697 related articles for article (PubMed ID: 33629601)
1. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
Nguyen X; Hooper M; Borlagdan JP; Palumbo A
Ann Pharmacother; 2021 Nov; 55(11):1410-1418. PubMed ID: 33629601
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
Narayan P; Osgood CL; Singh H; Chiu HJ; Ricks TK; Chiu Yuen Chow E; Qiu J; Song P; Yu J; Namuswe F; Guiterrez-Lugo M; Hou S; Pierce WF; Goldberg KB; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
Clin Cancer Res; 2021 Aug; 27(16):4478-4485. PubMed ID: 33753456
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
4. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.
Iwata TN; Sugihara K; Wada T; Agatsuma T
PLoS One; 2019; 14(10):e0222280. PubMed ID: 31574081
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I;
N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192
[TBL] [Abstract][Full Text] [Related]
6. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
[TBL] [Abstract][Full Text] [Related]
7. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
8. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
Narayan P; Dilawari A; Osgood C; Feng Z; Bloomquist E; Pierce WF; Jafri S; Kalavar S; Kondratovich M; Jha P; Ghosh S; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
J Clin Oncol; 2023 Apr; 41(11):2108-2116. PubMed ID: 36780610
[TBL] [Abstract][Full Text] [Related]
9. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Takegawa N; Tsurutani J; Kawakami H; Yonesaka K; Kato R; Haratani K; Hayashi H; Takeda M; Nonagase Y; Maenishi O; Nakagawa K
Int J Cancer; 2019 Dec; 145(12):3414-3424. PubMed ID: 31087550
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
[TBL] [Abstract][Full Text] [Related]
12. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Adams E; Wildiers H; Neven P; Punie K
ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
Nie T; Blair HA
Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T;
Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.
Xu H; Zhang H; Guo W; Zhong X; Sun J; Zhang T; Wang Z; Ma X
BMC Cancer; 2022 Aug; 22(1):923. PubMed ID: 36028823
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials.
Ma R; Shi Y; Yan R; Yin S; Bu H; Huang J
Crit Rev Oncol Hematol; 2024 Apr; 196():104305. PubMed ID: 38442809
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma.
Kang C
Target Oncol; 2023 Nov; 18(6):981-989. PubMed ID: 37787931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
